Application No.: 10/593,786 Docket No.: 350292003100

AMENDMENTS

In the Claims:

- (Currently Amended) An antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH₂ (4447).
- (Currently Amended) An antibody subtype (2) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which both C-terminals of the heavy chain are Pro-NH; (447).
- 3. (Currently Amended) The antibody subtype according to claim 1 or 2 wherein the heavy chain of the native humanized PM-1 antibody corresponding to the subtype according to claim 1 or 2 has a heavy chain that corresponds to amino acids 1-448 of an amino acid sequence set forth in SEQ ID NO: 1, and a heavy chain of the subtype antibody having the C-terminal Pro-NH₂ corresponds to amino acids 1-447 of SEQ ID NO:1.
- (Original) The antibody subtype according to claim 3 wherein glutamine (Gln) at the heavy chain N-terminal is pyroglutamic acid (pGlu).
- (Currently Amended) The antibody subtype according to claim any one of claims 1, to 4
 wherein the light chain of the above humanized PM-1 antibody subtype has an amino acid sequence
 set forth in SEQ ID NO: 2.
- (Currently Amended) A pharmaceutical composition comprising either the antibody subtype (1) of claim 1 or the subtype (2) described in any one of claims 1-5, or both of the subtypes (1) and (2).
- (New) The antibody subtype according to claim 2, wherein the light chain of the above humanized PM-1 antibody subtype has an amino acid sequence set forth in SEQ ID NO: 2.
 - 8. (New) A pharmaceutical composition comprising the antibody subtype (2) of claim 2.

Application No.: 10/593,786 Docket No.: 350292003100

9. (New) A pharmaceutical composition comprising: an antibody subtype (1) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which one C-terminal of the heavy chain is Pro-NH₂; and an antibody subtype (2) which is a subtype of the humanized PM-1 antibody against interleukin-6 receptor (IL-6R) and in which both C-terminals of the heavy chain are Pro-NH₂.